Senolytics
Senolytics scored 6.6 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Botanical Extract (non-adaptogenic).
Senolytics are compounds intended to clear senescent cells. Fisetin plus quercetin has strong mouse and human-tissue rationale from Yousefzadeh 2018 but still has no published human F+Q efficacy trial; D+Q has small human pilots in IPF and diabetic kidney disease.
What is Senolytics?
Senolytics are compounds designed to clear senescent cells: damaged, stress-adapted cells that stop dividing but refuse to die. In small amounts, senescence protects you from cancer and helps with wound healing. When senescent cells persist, they secrete SASP, an inflammatory mix of cytokines, proteases, and growth signals that can damage nearby tissue and spread dysfunction.
The common OTC version is F+Q: fisetin plus quercetin. The prescription research version is D+Q: dasatinib plus quercetin. The logic comes from senescent-cell anti-apoptotic pathways, especially BCL-2, BCL-xL, PI3K, and AKT. Zhu 2015 showed that senescent cells rely on these survival pathways. Zhu 2017 then identified fisetin as senolytic in selected cell types, and Yousefzadeh 2018 made fisetin the best-known supplement candidate by showing reduced senescence markers and extended health and lifespan in mice.
That last phrase matters: in mice. Human evidence is much thinner. D+Q has small early pilots in IPF and diabetic kidney disease, while F+Q specifically still has no published human senolytic efficacy trial. Newer studies sharpen the caution: Farr 2024 missed its primary endpoint overall in a D+Q bone trial, and Shimizu 2025 found no overall primary or secondary endpoint benefit for a different senolytic botanical. Senolytics are real enough to take seriously, but not proven enough to treat like a routine longevity vitamin.
Terminology
For clinical-trial context, see the Chaib 2022 senolytics translation review.
- SASP: Senescence-Associated Secretory Phenotype. The inflammatory cytokine, protease, and signaling mixture released by senescent cells.
- BCL-2 / BCL-xL: Anti-apoptotic proteins that help some senescent cells resist programmed cell death.
- PI3K / AKT: Cell survival signaling pathway often upregulated in senescent cells.
- F+Q: Fisetin + quercetin. The OTC supplement stack most biohackers mean when they say senolytics.
- D+Q: Dasatinib + quercetin. Prescription senolytic combination with stronger human pilot evidence and higher risk.
- SCAP: Senescent-cell anti-apoptotic pathway. Survival pathway senolytics try to disable.
- p16 / p21: Cyclin-dependent kinase inhibitors used as senescence biomarkers.
- SA-beta-gal: Senescence-associated beta-galactosidase. A common senescence marker in cells and immune-cell assays.
- GRAS: Generally Recognized As Safe. FDA food-ingredient safety designation for specified uses, not disease treatment approval.
- GRN 341: FDA GRAS notice number for quercetin in specified food uses.
- AFFIRM-LITE: Mayo Clinic fisetin frailty RCT, NCT03675724.
- IPF: Idiopathic Pulmonary Fibrosis. A progressive lung-scarring disease studied in the D+Q pilot.
- HSC: Hematopoietic Stem Cell. A blood-forming stem cell compartment affected by senescence in animal studies.
- CYP3A4: Liver cytochrome P450 enzyme inhibited by quercetin during the dosing window.
- DOAC: Direct Oral Anticoagulant, such as apixaban or rivaroxaban.
How do you take Senolytics?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | Fisetin capsule (standardized extract) | N/A (no FDA-approved senolytic indication) | 1,000-2,000 mg, roughly 20 mg/kg body weight, for 2 consecutive days |
| oral | Quercetin capsule | N/A (no FDA-approved senolytic indication) | 1,000-1,250 mg for 2 consecutive days |
| oral | Dasatinib + Quercetin (D+Q, Rx) | Dasatinib 100 mg + quercetin 1,250 mg in early clinical pilot protocols | 3 consecutive days monthly |
Protocols
F+Q quarterly hit-and-run Anecdotal
- Dose
- Fisetin 1-2g + quercetin 1-1.25g
- Frequency
- Quarterly (every 3 months)
- Duration
- Indefinite cycling if appropriate
Community standard. Two consecutive days. Nick's protocol when he uses it. Avoid around procedures, anticoagulants, and high-risk medication windows.
F+Q extended pulse Anecdotal
- Dose
- Fisetin 1-2g + quercetin 1-1.25g
- Frequency
- 3 consecutive days monthly
- Duration
- Indefinite cycling if appropriate
Modeled after D+Q monthly dosing. Higher exposure than quarterly F+Q with no published human efficacy proof for this specific OTC combination.
D+Q clinical (under supervision) Clinical
- Dose
- Dasatinib 100 mg + quercetin 1,250 mg
- Frequency
- 3 consecutive days monthly in early pilot protocols
- Duration
- Per clinical guidance
Used in small pilots including [Justice 2019](https://pmc.ncbi.nlm.nih.gov/articles/PMC6412088/) and [Hickson 2019](https://pmc.ncbi.nlm.nih.gov/articles/PMC6796530/). Requires prescription and medical monitoring.
Post-chemotherapy / radiation Anecdotal
- Dose
- F+Q quarterly dosing
- Frequency
- Quarterly
- Duration
- 6-12 months post-treatment only if oncology clears it
Emerging protocol for treatment-induced senescence. Do not self-prescribe around active cancer, immunotherapy, targeted therapy, surgery, or radiation without oncology review.
Biomarker-guided senolytic timing Anecdotal
- Dose
- F+Q or clinical senolytic strategy based on senescence-marker panel
- Frequency
- Per biomarker reading
- Duration
- Ongoing reassessment
Research-stage idea. p16 / p21, SA-beta-gal, SASP panels, and gerodiagnostics are not yet standardized for consumer decision-making.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of Senolytics?
Upside contribution: 1.80
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.4 | 0.600 | |
| Breadth | 15% | 4.0 | 0.600 | |
| Evidence | 25% | 2.0 | 0.500 | |
| Speed | 10% | 3.0 | 0.300 | |
| Durability | 10% | 3.2 | 0.320 | |
| Bioindividuality | 15% | 3.2 | 0.480 | |
| Total | 2.800 |
Upside Rationale
Efficacy. Senolytics earns a modest efficacy read because the strongest signal is preclinical and the human benefit on hard endpoints is still unproven. Yousefzadeh 2018 found fisetin was the most potent senotherapeutic among tested flavonoids and extended health and lifespan in mice given it late in life, while Justice 2019 and Hickson 2019 reported feasibility and senescence marker movement in tiny pilots. None of that proves senolytics improve how long or how well people live. The clearest tempering comes from the Farr 2024 bone trial, where senolytics missed the primary bone endpoint overall in postmenopausal women. Senolytics may move biomarkers, but durable clinical efficacy in humans is not yet established, so the modest score is honest rather than pessimistic.
Breadth of Benefits. Senolytics score well on breadth because senescent cells are a systemic feature of aging, so the theoretical reach is wide even though human proof is narrow. Senescent cells accumulate across adipose, vascular, immune, lung, kidney, brain, skin, bone, and stem cell compartments, which is why the class is studied for so many conditions. Xu 2018 showed senolytic treatment improved physical function and post-treatment survival in old mice, and Chang 2016 supports stem cell rejuvenation in mouse blood and muscle. The honest framing is that senolytics breadth reflects class biology in animals more than confirmed multi-system benefit in people. The best human candidates for senolytics are older adults or those with high senescent-cell burden, not healthy young optimizers.
Evidence Quality. Evidence is the binding constraint for senolytics, which is why this dimension sits low and the overall confidence stays Low. There are strong mouse studies and early pilots, but no published efficacy trial validates the over-the-counter fisetin-plus-quercetin combination most readers will actually use. Guan 2024 reviewed dozens of dietary-ingredient senescence studies and found only a handful in humans, with risk of bias largely unclear. Shimizu 2025 was a completed human RCT that came back null overall, and Farr 2024 missed its primary endpoint. The senolytics signal is genuinely sparse rather than buried, so the score reflects thin, mechanism-dominant evidence and null human outcomes, not a recording penalty for missing trials.
Speed of Onset. Senolytics work on a timeline of weeks rather than hours, which lands this dimension in the middle. The Hickson 2019 pilot measured senescence-associated markers across an eleven-day window after dosing, which supports relatively quick biomarker movement for the class. Functional changes in small pilots, where they appear at all, emerge over weeks. For the consumer fisetin-plus-quercetin version there is no verified human onset timeline, so any expectation is borrowed from the drug-pair work. The reasonable mental model for senolytics is that SASP signaling may fall first, and any tissue-level or subjective change would only follow over several weeks, and only if the user carried enough senescent-cell burden to matter in the first place.
Durability. Senolytics score moderately on durability because the hit-and-run design is the whole appeal: clear a persistent senescent cell and that specific cell does not come back when the compound leaves circulation. The catch is that senescent cells reaccumulate over time through ordinary aging, chronic disease, injury, obesity, and metabolic stress, so any benefit is not permanent. Quarterly or intermittent dosing is a practical guess drawn from the biology and from published senolytic schedules, not a proven maintenance protocol for the supplement combination. That makes senolytics more durable than a daily anti-inflammatory you must keep taking, but less certain than a lifestyle change you can sustain and actually measure over years.
Bioindividuality. Senolytics are highly bioindividual, because response should track baseline senescent-cell burden far more than chronological age. Older adults and people with fibrosis, diabetes, obesity, chronic kidney disease, prior chemotherapy, or chronic inflammation plausibly have more target cells to clear, while younger and healthier users likely have little to gain and more theoretical downside, since senescence also helps suppress tumors and coordinate repair. Baseline senescent-cell burden may predict response to senolytics better than chronological age alone. That is why future biomarker-guided senolytics are more compelling than blind quarterly dosing, and why matching the person to the mechanism matters more here than for most interventions.
What are the risks & downsides of Senolytics?
Downside contribution: 0.51 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.5 | 0.450 | |
| Side effects | 15% | 1.4 | 0.210 | |
| Cost | 5% | 1.3 | 0.065 | |
| Effort | 5% | 1.2 | 0.060 | |
| Opportunity | 5% | 1.3 | 0.065 | |
| Dependency | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.375 | |||
| Harm subtotal × 1.4 | 1.659 | |||
| Opportunity subtotal × 1.0 | 0.190 | |||
| Combined downside | 1.849 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.509 |
Downside Rationale
Safety risk. Senolytics, as the typical reader will use them, are benign, because the real-world protocol is over-the-counter fisetin and quercetin, two dietary flavonoids with a long history of safe human consumption and no intrinsic organ toxicity at sensible intermittent doses. That is what this low score reflects. The genuine but separate caution is the prescription path: the Dasatinib plus Quercetin combination relies on dasatinib, an oncology tyrosine kinase inhibitor with real intrinsic toxicity including myelosuppression, bleeding risk, fluid retention, and cardiovascular and pulmonary effects. That toxicity belongs in the Verdict as an avoid-unless-physician-supervised caveat for the drug route, not as the core safety basis for the flavonoid protocol most people run. Even the benign OTC version still warrants ordinary care around anticoagulant use, perioperative timing, pregnancy, severe organ disease, and active cancer, where clearing senescent cells could remove tumor-suppressing brakes.
Side effect profile. Senolytics in their common over-the-counter form are well tolerated, with mild gastrointestinal discomfort, nausea, or loose stool from high-dose fisetin being the usual ceiling, and gram-range quercetin generally passing uneventfully aside from occasional headache, tingling, or interaction risk in sensitive users. The intermittent structure helps: a couple of days per quarter is far easier to tolerate than daily dosing. The prescription dasatinib path is a different category entirely, since the drug drives the cytopenia and bleeding-adjacent effects that earn the oncology route its pharmaceutical-grade caution, and those effects should never be casually generalized down to the flavonoid combination that defines the everyday senolytics protocol.
Financial cost. Senolytics are inexpensive by longevity standards, which keeps this dimension low. The over-the-counter fisetin-plus-quercetin cycle typically runs roughly thirty to fifty-five dollars per quarter, or about one hundred twenty to two hundred twenty dollars a year, with no device, subscription, lab panel, or clinic visit strictly required, although a medication review is wise. The prescription route costs more and adds physician oversight on top of the drug itself. For most readers the dollar cost of senolytics is a minor consideration compared with whether the mechanism even applies to them, so cost should not be the deciding factor in either direction, and money saved here means little if the intervention was never matched to a real senescent-cell burden in the first place.
Time and effort burden. Senolytics are among the lowest-effort interventions in the archive, which is why this score is so low. The mechanical burden is trivial: two days of capsules per quarter. The real effort is judgment rather than logistics, which means reviewing drug interactions, avoiding the dosing window around surgery or procedures, timing doses with meals, and honestly deciding whether you are old enough or high-burden enough for senolytics to plausibly do anything. That thinking is light compared with training, sleep work, or dietary change, but skipping it is where most of the avoidable risk in this intervention lives.
Opportunity cost. Senolytics carry low opportunity cost because a quarterly protocol does not displace exercise, sleep, protein, creatine, sauna, or cardiometabolic work, which all remain available. The genuine risk is psychological rather than logistical: treating senolytics as a shortcut while neglecting the fundamentals that lower senescent-cell formation in the first place. If someone is chronically inflamed because they sleep five hours and never train, a quarterly fisetin dose is not the bottleneck, and leaning on senolytics to paper over those gaps is the main way this otherwise cheap intervention can quietly cost you the gains that the fundamentals would have delivered for free.
Dependency and withdrawal. Senolytics have essentially no dependency or withdrawal profile, which is why this is the lowest-risk dimension. Fisetin and quercetin are absent from the body for nearly the entire quarter, and there is no receptor adaptation or withdrawal syndrome to manage. Stopping simply means you stop applying intermittent senolytic pressure, with no rebound to taper around. Any benefit fades only as new senescent cells reaccumulate through normal biology over time, which is a gradual return to baseline rather than a crash, and nothing about the protocol creates a craving, tolerance, or physiological need to keep taking it on schedule.
Reversibility. Senolytics wash out cleanly at the whole-body level, since intermittent flavonoid dosing leaves no lingering compound and no system to wind down, which is why this dimension stays low. The one genuine caveat is cellular: clearing a persistent senescent cell is the entire point, and you cannot bring that specific cell back once it is gone. If senolytics happened to clear cells doing useful work in tumor suppression, tissue repair, wound healing, or adaptive remodeling, stopping the supplement does nothing to restore them. For the over-the-counter fisetin-plus-quercetin protocol the probability of meaningful collateral harm appears low, so senolytics read as easily reversible in practice while you stay mindful that the intended action is targeted cell death.
Is Senolytics worth it?
Senolytics is a 6.6 / 10 fit for longevity, healthspan, cellular senescence, especially for readers who can match the protocol to age, disease context, drug interactions, and whether the protocol is supervised. The best evidence anchors are Shimizu et al. 2025, which RCT n=110 randomized; no statistically significant overall primary or secondary endpoint changes; male subgroup CD8+ high-SA-beta-gal signal only, and Guan et al. 2024, which 83 included articles; 78 animal studies and 5 human studies; human dietary-senotherapeutic evidence limited with unclear risk of bias. Senolytics are compounds intended to clear senescent cells. That makes the intervention most useful when the reader wants the studied outcome, accepts the evidence limits, and can track whether the response shows up.
✅ Best for: Adults over 50 with measurable signs of age-related decline, chronic low-grade inflammation, reduced physical function, fibrotic conditions, metabolic disease, or high suspected senescent-cell burden. Biohackers who want to explore the senolytic mechanism without dasatinib's prescription-drug risk. People who understand that F+Q is a low-cost experiment, not a proven longevity therapy. Older users who can review CYP3A4 and anticoagulant interactions before a short dosing window. Patients considering D+Q only under clinician supervision, especially where early human pilots such as Justice 2019 or Hickson 2019 are relevant to their condition.
❌ Avoid if: You are under 40 with no signs of accelerated aging. You have active cancer or recent cancer history unless your oncologist explicitly clears it. You take warfarin, a direct oral anticoagulant, high-dose aspirin, or high-risk CYP3A4-dependent medications. You are pregnant, breastfeeding, preparing for surgery, dealing with severe liver or kidney disease, or expecting Phase 3-level proof. Avoid D+Q without medical supervision. No FDA approval, Cochrane synthesis, USPSTF recommendation, NICE endorsement, or IPF society guideline supports senolytics for healthy aging as of the 2026-05-03 audit.
What is Senolytics best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Longevity / Lifespan: 6.8/10
Score: 6.8/10Senolytics scores 6.8/10 for longevity, with the best signal coming from Shimizu et al. 2025. Yousefzadeh 2018 supports fisetin lifespan and healthspan effects in mice; Farr 2024 tempers human extrapolation for D+Q. The score stays bounded because Senolytics evidence for longevity can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Healthspan: 7.0/10
Score: 7.0/10For healthspan, Senolytics lands at 7.0/10 because Guan et al. 2024 supports the core mechanism. Xu 2018 found D+Q improved physical function and post-treatment survival in old mice; human healthspan outcomes remain unproven. The score stays bounded because Senolytics evidence for healthspan can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cellular Senescence: 8.2/10
Score: 8.2/10The cellular senescence use case earns 8.2/10 for Senolytics, anchored by Silva et al. 2024. Direct mechanism: Zhu 2015 identified senescent-cell anti-apoptotic pathway vulnerabilities; Zhu 2017 identified fisetin as senolytic in selected cell types. The score stays bounded because Senolytics evidence for cellular senescence can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Anti-Inflammatory: 7.0/10
Score: 7.0/10Evidence puts Senolytics at 7.0/10 for anti inflammatory, mainly through Farr et al. 2024. SASP suppression is central to the mechanism; Hickson 2019 supports marker movement for D+Q but is preliminary and corrected-conclusion-sensitive. The score stays bounded because Senolytics evidence for anti inflammatory can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Immune Function: 6.0/10
Score: 6.0/10A cautious immune function score of 6.0/10 fits Senolytics, with Baker et al. 2011 preventing a stronger claim. Shimizu 2025 found no overall primary immune endpoint benefit for APE, but did report a male subgroup CD8+ senescence-marker signal. The score stays bounded because Senolytics evidence for immune function can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Bone / Joint Health: 6.5/10
Score: 6.5/10A 6.5/10 bone joint rating fits Senolytics, since Hickson et al. 2019 points to a real but bounded effect. Bone rationale is strong preclinically, but Farr 2024 found D+Q did not improve the primary bone resorption endpoint overall. The score stays bounded because Senolytics evidence for bone joint can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Antioxidant / Oxidative Stress: 6.5/10
Score: 6.5/10Antioxidant is a 6.5/10 fit for Senolytics, based on the evidence summarized in Lee et al. 2024. Both fisetin and quercetin are flavonoid polyphenols; Guan 2024 found dietary senotherapeutic evidence is mostly animal-level and human evidence remains limited. The score stays bounded because Senolytics evidence for antioxidant can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Stem Cell Support: 6.5/10
Score: 6.5/10The use-case math gives Senolytics 6.5/10 for stem cell, guided by Guan et al. 2024. Chang 2016 showed ABT263 cleared senescent cells and rejuvenated aged mouse hematopoietic and muscle stem-cell compartments; F+Q translation is unknown. The score stays bounded because Senolytics evidence for stem cell can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Respiratory: 6.3/10
Score: 6.3/10The evidence-weighted call is 6.3/10 for Senolytics in respiratory, led by Yousefzadeh et al. 2018. Justice 2019 IPF pilot found feasibility and physical-function signals with D+Q, not F+Q, with no control group. The score stays bounded because Senolytics evidence for respiratory can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cardiovascular: 6.2/10
Score: 6.2/10Senolytics reaches 6.2/10 for cardiovascular when the goal matches the population in Chaib et al. 2022. Senescent endothelial-cell clearance supports vascular function in preclinical models; human cardiovascular outcome data for F+Q is absent. The score stays bounded because Senolytics evidence for cardiovascular can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Skin / Beauty: 6.2/10
Score: 6.2/10Senolytics is a 6.2/10 option for skin beauty, especially where the context resembles Chang et al. 2016. Senescent fibroblast clearance fits skin-aging theory, but no human F+Q skin-aging outcome trial was verified in the audit. The score stays bounded because Senolytics evidence for skin beauty can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Kidney Function: 6.0/10
Score: 6.0/10For readers tracking kidney function, Senolytics deserves 6.0/10 because Justice et al. 2019 gives the strongest anchor. Hickson 2019 reported D+Q senescence-marker reductions in diabetic kidney disease, but it was small, preliminary, and later corrected. The score stays bounded because Senolytics evidence for kidney function can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Neuroprotection: 6.0/10
Score: 6.0/10The strongest neuroprotection argument for Senolytics is worth 6.0/10, with Zhu et al. 2017 as the anchor. Senescent glial-cell clearance remains a research target; Chaib 2022 frames neurodegeneration as promising but clinically early. The score stays bounded because Senolytics evidence for neuroprotection can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Metabolic Health: 6.0/10
Score: 6.0/10In metabolic health, Senolytics rates 6.0/10 because Baker et al. 2016 supports selective use. Senescent preadipocyte and adipose-inflammation mechanisms are plausible from preclinical D+Q work, but F+Q human metabolic endpoints are not proven. The score stays bounded because Senolytics evidence for metabolic health can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Telomere / DNA Repair: 5.8/10
Score: 5.8/10Senolytics earns 5.8/10 in telomere dna because Shimizu et al. 2025 supports the main pathway. Lee 2024 found concerning first-generation clock and telomere signals with DQ, while second and third-generation clocks were not significant. The score stays bounded because Senolytics evidence for telomere dna can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Recovery / Repair: 5.8/10
Score: 5.8/10The recovery repair evidence puts Senolytics at 5.8/10, helped by Lee et al. 2024. Tissue remodeling depends on balanced senescence and clearance; Chaib 2022 stresses clinical translation is still early. The score stays bounded because Senolytics evidence for recovery repair can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Autophagy: 5.5/10
Score: 5.5/10The practical autophagy read is 5.5/10 for Senolytics, with Gonzales et al. 2023 setting the ceiling. Indirect via cellular renewal after senescent-cell clearance; no direct human F+Q autophagy-marker trial was verified in the audit. The score stays bounded because Senolytics evidence for autophagy can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cognition / Focus: 5.5/10
Score: 5.5/10Senolytics has a 5.5/10 cognition focus case because Xu et al. 2018 supports a plausible benefit. Gonzales 2023 was a 5-person Alzheimer's feasibility trial of D+Q; it supports CNS-penetrance questions, not cognitive efficacy. The score stays bounded because Senolytics evidence for cognition focus can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Mitochondrial: 5.5/10
Score: 5.5/10The mitochondrial score sits at 5.5/10 for Senolytics, reflecting the evidence in Zhu et al. 2015. Senescent cells often carry mitochondrial dysfunction; clearing them may improve tissue pool quality, but this is indirect for F+Q. The score stays bounded because Senolytics evidence for mitochondrial can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Injury Recovery: 5.5/10
Score: 5.5/10Senolytics belongs at 5.5/10 for injury recovery, with Farr et al. 2024 supporting the practical upside. Senescent cells can impair repair but also assist wound healing in specific contexts, making timing critical and human evidence insufficient. The score stays bounded because Senolytics evidence for injury recovery can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Methylation Support: 5.5/10
Score: 5.5/10A 5.5/10 rating for methylation is fair for Senolytics, because Gonzales et al. 2023 supports limited benefit. Lee 2024 found mixed methylation-clock effects, including first-generation clock acceleration signals after DQ. The score stays bounded because Senolytics evidence for methylation can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Energy / Fatigue: 5.5/10
Score: 5.5/10Senolytics gets 5.5/10 for energy, with Chaib et al. 2022 giving the cleanest evidence anchor. Reduced SASP inflammation may improve subjective energy in older or inflamed users, but human F+Q energy outcomes remain untested. The score stays bounded because Senolytics evidence for energy can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Hormonal / Endocrine: 5.0/10
Score: 5.0/10For hormonal, the 5.0/10 score reflects how Senolytics performs in Silva et al. 2024. Any endocrine benefit is indirect through metabolic and inflammatory-cell senescence; no verified human hormonal F+Q endpoint exists. The score stays bounded because Senolytics evidence for hormonal can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Libido / Sexual Health | 4.8 | Potential benefit is indirect through metabolic and hormonal improvements; no verified libido trial exists for F+Q or D+Q. |
Frequently Asked Questions
What are senolytics and how do they work?
Senolytics are compounds that selectively push some senescent cells into apoptosis by weakening survival pathways such as BCL-2, BCL-xL, PI3K, and AKT. Zhu 2015 identified these senescent-cell anti-apoptotic pathways as drug targets. The goal is to lower SASP, the inflammatory signal cloud secreted by persistent senescent cells. The idea is elegant, but human proof for OTC F+Q is still missing, especially for healthy longevity users. That is why age and disease burden matter so much.
Fisetin + quercetin vs dasatinib + quercetin: which is better?
D+Q has stronger human pilot evidence; F+Q has the better consumer safety and access profile. Justice 2019 and Hickson 2019 used prescription D+Q in small human pilots. F+Q relies mostly on fisetin mouse and cell evidence from Yousefzadeh 2018. Dasatinib adds serious prescription-drug risks, so D+Q belongs under clinician supervision, not casual experimentation. For most readers, F+Q is the safer first experiment.
Does fisetin actually work as a senolytic in humans?
Not yet as a proven clinical intervention. Yousefzadeh 2018 showed fisetin reduced senescence markers and extended health and lifespan in mice, with supportive human adipose explant data. But that is not a human outcome trial. AFFIRM-LITE, COVID-FISETIN, and STOP-Sepsis are the kinds of trials needed to close the gap.
How do I run a senolytic protocol?
The common OTC protocol is fisetin 1,000-2,000 mg plus quercetin 1,000-1,250 mg for 2 consecutive days, repeated quarterly. Take with a fat-containing meal. Review medications first because quercetin inhibits CYP3A4, and both compounds can matter around anticoagulants or bleeding risk. Daily dosing misses the point. Senolytics are usually treated as hit-and-run pulses because the target cells take time to reaccumulate.
Are senolytics safe?
F+Q is usually well tolerated, but the safety story is mostly interaction-driven. Expect occasional GI discomfort at high fisetin doses. The bigger concerns are anticoagulants, CYP3A4-metabolized drugs, active cancer, pregnancy, severe kidney or liver disease, and perioperative timing. D+Q is different: dasatinib is an oncology drug with risks including myelosuppression, bleeding, fluid retention, pulmonary arterial hypertension, QT prolongation, and hepatotoxicity.
When should I start taking senolytics?
Age 50+ is the more defensible starting zone because senescent-cell burden rises with age and chronic disease. Yousefzadeh 2018 treated mice late in life, which matches the idea that higher burden creates more upside. Younger healthy adults probably have little to clear and more uncertainty. Chronic disease, obesity, fibrosis, chemotherapy exposure, or accelerated aging may shift the decision earlier, but that should be individualized with medication review. A clinician can help sort that risk.
Who should avoid senolytics?
Avoid senolytics if you have active cancer or recent cancer history unless your oncologist clears it. Senescence can be tumor-suppressive. Also avoid unsupervised use with warfarin, direct oral anticoagulants, high-dose aspirin, strong CYP3A4-dependent medications, pregnancy, breastfeeding, severe renal disease, severe liver disease, or upcoming surgery. Young healthy adults under 40 with no accelerated-aging signal are a poor risk-reward fit.
Why is the BioHarmony score only 6.8 if the mouse data looks strong?
The score is capped by translation risk. The mouse data is strong, but F+Q has no published human senolytic efficacy trial. Farr 2024 found a null primary endpoint in a D+Q bone RCT, and Shimizu 2025 was mostly null overall for a different senolytic botanical. No FDA, Cochrane, USPSTF, NICE, or IPF society endorsement supports consumer senolytic use for healthy aging.
What could change Senolytics's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| AFFIRM-LITE publishes positive fisetin senolytic data | Evidence 1.8 to 3.0; Efficacy 2.5 to 3.2 | 7.2 / 10 💪 Strong recommend |
| D+Q Phase 3 RCT validates senolytic class in n>200 adults | Evidence 1.8 to 2.8; Efficacy 2.5 to 3.0 | 7.1 / 10 💪 Strong recommend |
| CYP3A4 interaction causes serious harm in a combination user | Safety 1.5 to 2.5 | 6.1 / 10 👍 Worth trying |
| Yousefzadeh mouse lifespan extension fails to replicate | Efficacy 2.5 to 1.8 | 6.4 / 10 👍 Worth trying |
| 5-year follow-up data confirms zero serious safety issues in 200+ F+Q users | Safety 1.5 to 1.2 | 6.8 / 10 👍 Worth trying |
| Epigenetic-clock acceleration signal is confirmed in larger controlled trials | Safety 1.5 to 2.5; Efficacy 2.5 to 2.0 | 6.0 / 10 👍 Worth trying |
Key Evidence Sources
- Shimizu et al. 2025 - Preliminary Data on the Senolytic Effects of Agrimonia pilosa Ledeb. Extract Containing Agrimols for Immunosenescence in Middle-Aged Humans, Nutrients. RCT n=110 randomized; no statistically significant overall primary or secondary endpoint changes; male subgroup CD8+ high-SA-beta-gal signal only
- Guan et al. 2024 - Therapeutic effect of dietary ingredients on cellular senescence in animals and humans: systematic review, Ageing Research Reviews. 83 included articles; 78 animal studies and 5 human studies; human dietary-senotherapeutic evidence limited with unclear risk of bias
- Silva et al. 2024 - STOP-Sepsis fisetin protocol, Trials. Protocol only; planned n=220 older sepsis patients; no efficacy results available
- Farr et al. 2024 - Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women, Nature Medicine. Phase 2 RCT n=60; D+Q did not improve the primary CTx endpoint overall; no serious adverse events reported
- Lee et al. 2024 - Effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks, Aging. Longitudinal pilot n=19 per phase; DQ increased first-generation clock acceleration signals; second and third-generation clock effects were not significant
- Gonzales et al. 2023 - Senolytic therapy in mild Alzheimer's disease: phase 1 feasibility trial, Nature Medicine. Open-label feasibility trial; 5 participants completed 12 weeks; evaluates CNS penetrance, safety, and feasibility, not efficacy
- Chaib et al. 2022 - Cellular senescence and senolytics: the path to the clinic, Nature Medicine. Clinical translation review; stresses that senolytics should not be endorsed for OTC disease prevention or treatment before rigorous clinical trials
- Hickson et al. 2019 - Senolytics decrease senescent cells in humans: preliminary D+Q diabetic kidney disease report, EBioMedicine. Small preliminary human trial n=14; reported senescence-marker changes with later corrigendum requiring caution around exact numerical claims
- Justice et al. 2019 - Senolytics in idiopathic pulmonary fibrosis: first-in-human open-label pilot, EBioMedicine. Open-label IPF pilot n=14; D+Q feasible with physical-function signals and no control group
- Yousefzadeh et al. 2018 - Fisetin is a senotherapeutic that extends health and lifespan, EBioMedicine. Fisetin reduced senescence markers in mice and human adipose tissue explants; extended mouse health and lifespan; no human clinical outcome proof
- Xu et al. 2018 - Senolytics improve physical function and increase lifespan in old age, Nature Medicine. D+Q preclinical proof-of-concept; improved physical function and post-treatment survival in old mice
- Zhu et al. 2017 - New agents that target senescent cells: fisetin and BCL-XL inhibitors, Aging. Identified fisetin as senolytic in selected senescent human endothelial cells, with cell-type specificity
- Baker et al. 2016 - Naturally occurring p16Ink4a-positive cells shorten healthy lifespan, Nature. Genetic senescent-cell clearance extended median mouse lifespan and delayed organ deterioration without apparent side effects
- Chang et al. 2016 - Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice, Nature Medicine. ABT263 cleared senescent cells and rejuvenated aged mouse hematopoietic and muscle stem-cell compartments
- Zhu et al. 2015 - The Achilles' heel of senescent cells: from transcriptome to senolytic drugs, Aging Cell. Foundational SCAP-targeting paper that identified senescent-cell survival pathway vulnerabilities
- Baker et al. 2011 - Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders, Nature. Foundational INK-ATTAC mouse experiment showing senescent-cell clearance delayed age-associated phenotypes
What does the evidence say about Senolytics?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
On the Outliyr Podcast, Kyle VanderLeest noted: “using fisetin and apigenin, they’re really good for reducing cellular senescence.” (EP209).
Citations: Shimizu 2025, Guan 2024, Silva 2024, Farr 2024, Lee 2024, Gonzales 2023, Hickson 2019, Justice 2019, Yousefzadeh 2018, Xu 2018
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Hayflick 1961, Baker 2011, Zhu 2015, Baker 2016, Yousefzadeh 2018
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Senolytics
All lenses point in the same broad direction but with different strength. Modern science gives the cleanest mechanism and early human pilots, scientific history shows senescent-cell clearance repeatedly works in mice, and traditional food use supports general flavonoid exposure. They do not converge on a proven anti-aging protocol. The honest synthesis: senolytics are one of the more interesting longevity mechanisms, but F+Q is still an experiment for older or higher-burden users, not a validated maintenance supplement for healthy young adults.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- hs-CRP Baseline (pre-protocol) Post | Expected Down
- WBC During | Expected Stable
- Platelets During | Expected Stable
- ALT During | Expected Stable
- AST During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Watch | Primary
- Energy During | Expected Watch | Secondary
- Calm During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Post-Dose Fatigue Scale 1-5 | During | Expected Watch
- Joint Comfort Scale 1-5 | During | Expected Up
- GI Comfort Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Jaundice or yellowing of eyes
- Dark urine with right upper quadrant pain
- ALT or AST above 3x baseline
- Easy bruising or infection symptoms
Other interventions for Longevity
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.800 − 0.509 = 1.291
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.291 / 4.00) × 5 = 6.6 / 10
Further learning
8 Best Senolytic Supplements to Rid Your “Zombie” Cells & Extend Healthspan
Senolytics help rid the body of defective cells and appear to slow the aging process.
Latest Insights from 53+ Longevity Experts
What are the hallmarks of aging? How exactly does our diet relate to our longevity and age-related issues? Chris Burres gives us the inside…
